Collagen-induced Arthritis Is Reduced in 5-Lipoxygenase-activating Protein-deficient Mice by Griffiths, Richard J. et al.
 
1123
 
J. Exp. Med. 
 
Ó
 
 The Rockefeller University Press • 0022-1007/97/03/1123/07 $2.00
Volume 185, Number 6, March 17, 1997 1123–1129
 
Collagen-induced Arthritis Is Reduced in
5-Lipoxygenase-activating Protein-deﬁcient Mice
 
By Richard J. Grifﬁths,
 
*
 
 MaryAlice Smith,
 
*
 
 Marsha L. Roach,
 
‡
 
 Jeffrey 
L. Stock,
 
‡
 
 Ethan J. Stam,
 
*
 
 A.J. Milici,
 
*
 
 Deborah N. Scampoli,
 
*
 
 James 
D. Eskra,
 
*
 
 Robert S. Byrum,
 
§
 
 Beverly H. Koller,
 
§
 
and John D. McNeish
 
‡
 
From the 
 
*
 
Department of 
 
*
 
Cancer, Immunology, and Infectious Diseases, 
 
‡
 
Department of Molecular 
Sciences, Central Research Division, Pﬁzer, Inc., Groton, Connecticut 06340; and 
 
§
 
Curriculum in 
Genetics and Molecular Biology and Department of Medicine, University of North Carolina, Chapel 
Hill, North Carolina 27599-7248
 
Summary
 
Collagen-induced arthritis in the DBA/1 mouse is an experimental model of human rheuma-
toid arthritis. To examine the role of leukotrienes in the pathogenesis of this disease, we have
developed embryonic stem (ES) cells from this mouse strain. Here, we report that DBA/1 mice
made deficient in 5-lipoxygenase-activating protein (FLAP) by gene targeting in ES cells de-
velop and grow normally. Zymosan-stimulated leukotriene production in the peritoneal cavity
of these mice is undetectable, whereas they produce substantial amounts of prostaglandins. The
inflammatory response to zymosan is reduced in FLAP-deficient mice. The severity of col-
lagen-induced arthritis in the FLAP-deficient mice was substantially reduced when compared
with wild-type or heterozygous animals. This was not due to an immunosuppressive effect, be-
cause anti-collagen antibody levels were similar in wild-type and FLAP-deficient mice. These
data demonstrate that leukotrienes play an essential role in both the acute and chronic inflam-
matory response in mice.
 
L
 
eukotrienes are a class of biologically active lipids that
have a variety of proinflammatory effects (1, 2). Leu-
kotriene B
 
4
 
 (LTB
 
4
 
)
 
1
 
 is a chemotactic and activating factor
for leukocytes (3), whereas the peptido-leukotrienes, LTC
 
4
 
and LTD
 
4
 
, are potent constrictors of airway smooth muscle
and increase vascular permeability (4). The synthetic path-
way for leukotrienes is initiated by the release of arachi-
donic acid from the cell membrane by phospholipase A
 
2
 
,
followed by its conversion to LTA
 
4
 
 by the enzyme 5-lipox-
ygenase (5-LO) (5). In resting cells, 5-LO is found in the
cytosol, but upon activation it translocates predominately
to the nuclear membrane (6, 7). A second protein, 5-lipox-
ygenase-activating protein (FLAP) is an integral membrane
protein that is required for leukotriene synthesis (8). This
conclusion is based on both pharmacological and molecular
biological evidence. The pharmacological evidence was
provided by the discovery of a class of leukotriene synthesis
inhibitors that do not inhibit 5-LO but instead bind to
FLAP (9). The molecular biology evidence is based on exper-
iments involving transfection of the genes for 5-LO and FLAP
into an osteosarcoma cell line that normally express neither
of the genes. Only cells transfected with both genes synthe-
size leukotrienes (10). It was originally believed that FLAP
served as a docking protein for 5-LO but no direct interac-
tion between the two proteins has been demonstrated (11).
FLAP has sequence homology to LTC
 
4
 
 synthase, suggesting
that these proteins may be part of a larger gene family (12).
Leukotrienes play an important role in the allergic and
inflammatory response in both animals and humans (2).
Recently, using mice made genetically deficient in 5-LO
by homologous recombination in embryonic stem (ES) cells,
it has been demonstrated that 5-LO is not required for nor-
mal physiological functions, but is required for the full ex-
pression of certain acute inflammatory responses, e.g., platelet-
activating factor (PAF) lethality, arachidonic acid–induced
edema, and neutrophil infiltration in response to arachidonic
acid and immune complexes (13, 14). Mice made deficient
in FLAP also show reduced acute inflammatory responses to
these same stimuli, as described in the accompanying report.
Collagen-induced arthritis is an experimental model of
human rheumatoid arthritis that is dependent on both hu-
moral and cellular immunity to the immunizing antigen
(15). We have previously shown that LTB
 
4
 
 is required for
the development of collagen-induced arthritis in the mouse
 
1
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by utilizing a potent and selective receptor antagonist (16).
This conclusion has recently been questioned by a report
that a FLAP antagonist, which inhibits LTB
 
4
 
 production,
does not inhibit this disease unless coadministered with a
inhibitor of prostaglandin synthesis, suggesting that com-
bined inhibition of both leukotriene and prostaglandin pro-
duction is required to affect disease progression (17). We
now show that FLAP-deficient mice have a markedly re-
duced severity of disease in this model despite making high
levels of prostaglandins.
 
Materials and Methods
 
Reagents.
 
Zymosan A and IFA were obtained from Sigma (St.
Louis, MO). Chick type II collagen, and the anti-collagen mono-
clonal antibody A-2, were provided with the assistance of Dr. M.
Griffiths (University of Utah). Mycobacterium tuberculosis H37RA
was from Difco Laboratories, Inc. (Detroit, MI). Tetramethyl
benzidine Microwell peroxidase substrate was from Kirkgaard &
Perry Labs, Inc. (Gaithersburg, MD). The peroxidase-conjugated
rabbit antibody against mouse IgG was from Calbiochem Nova-
biochem (La Jolla, CA). Recombinant murine IL-1
 
a
 
 was ex-
pressed in 
 
Escherichia coli
 
 at Pfizer and purified as described (18).
 
Generation of FLAP-deficient Mice.
 
ES cells derived from DBA/1
inbred mice were transfected with a targeting vector designed to
inactivate FLAP in 129 ES cells (see accompanying manuscript).
Three different FLAP-targeted DBA 252 ES cell lines were in-
jected into day 3.5 blastocyst stage embryos from matings of
C57BL/6 mice by established procedures (19). Microinjected
blastocysts were transferred to pseudopregnant CD-1 females to
continue development to term. Chimeric males were mated with
DBA/1lacJ females and germline transmission of ES cell genome
was evident in offspring of dilute brown coat color (for thorough
description of DBA252 germline transmission and coat color, see
reference 20). Homozygous FLAP 
 
2
 
/
 
2
 
 were generated by
crossing heterozygous FLAP 
 
1
 
/
 
2
 
 males and females and geno-
types were identified by Southern blot analysis.
 
Zymosan-induced Peritonitis.
 
Male DBA/1 mice were injected
intravenously with 0.2 ml of a 10 mg/ml solution of Evans blue
dye to label plasma proteins. They were then injected intraperito-
neally with 0.5 ml of a 2 mg/ml suspension of zymosan. 30 or
180 min later the peritoneal cavity was lavaged with 3 ml of ice-
cold heparinzed saline (10 U/ml). The samples were centrifuged
to remove cells and debris and a 0.2-ml aliquot of the the super-
natant transfered to a microtiter plate. The absorbance of each
well was read at a wavelength of 650 nm on a Molecular Devices
plate reader. The remainder of the supernatant was stored frozen
at 
 
2
 
20
 
8
 
C until assayed for leukotriene and prostaglandin content.
 
Eicosanoid Assays.
 
The LTB
 
4
 
, LTE
 
4
 
, and 6-keto-PGF1
 
a
 
 con-
tent of the peritoneal lavage fluid was measured using commer-
cially available enzyme immunoassay (EIA) kits (Cayman Chemical,
Ann Arbor, MI) according to the instructions of the manufacturer.
The lower limit of detection at the dilutions used was 160 pg/ml
for the LTE
 
4
 
 and 6-keto-PGF1
 
a
 
 assays and 40 pg/ml for the
LTB
 
4
 
 assay. The LTE
 
4
 
 kit has a crossreactivity of 10% with LTC
 
4
 
and LTD
 
4
 
. Leukotrienes and hydroxyeicosatetraenoic acids (HETEs)
were extracted and analyzed by high performance liquid chroma-
tography with UV detection using a modification of our previ-
ously published methods (21, 22). Peritoneal lavage fluid was
spiked with 100 ng indomethacin in 10 
 
m
 
l methanol as an inter-
nal standard with or without a mixture of leukotriene and HETE
standards (25 ng each; Biomol, Plymouth Meeting, PA) and pro-
teins were precipitated by addition of 1.0 ml acetonitrile, fol-
lowed by centrifugation at 8,000 
 
g
 
 for 2 min. The supernatant
was acidified and diluted with 4.0 ml water/acetic acid (100:0.1,
vol/vol) containing 1 mM disodium EDTA (solvent A) and passed
through a BondElut C18 solid phase extraction cartridge (100 mg
in 1 ml column; Varian, Harbor City, CA) previously condi-
tioned with 4.0 ml methanol, 2.0 ml acetonitrile, and 1.0 ml sol-
vent A. The column was washed with 2.0 ml methanol/water
and 0.5 ml methanol/triethylamine (100:0.1, vol/vol) followed
by 0.5 ml methanol/acetic acid (100:0.1, vol/vol). Using a Per-
kin-Elmer ISS-100 autosampler fitted with a 2.0-ml stainless steel
loop, 500 
 
m
 
l of the eluate was injected into a Short One C18 col-
umn (10 
 
3
 
 0.46 cm, 3 
 
m
 
m; Rainin, Woburn, MA). The mobile
phase consisted of a linear gradient of methanol/water/trifluoroace-
tic acid (70:30:0.075 to 90:10:0.025, vol/vol/vol) over 30 min at a
flow rate of 1.5 ml/min by a Perkin-Elmer Series 4 quaternary
gradient pump. The column eluant was monitored by two Per-
kin-Elmer LC-95 UV detectors in series, one monitoring absor-
bance at 280 nm for detection of LTs and the other at 235 nm for
HETEs. The detector outputs were quantitated using two Per-
kin-Elmer LCI-100 integrators by comparison to external stan-
dard areas and corrected for recovery for each eicosanoid by
comparison of each sample run with and without these standards.
To confirm the identity of 12-HETE found in the peritoneal lav-
age by HPLC followed by EIA, and to confirm further the UV–
HPLC quantitation of the other eicosanoids in the samples, we
used another HPLC method using a mobile phase with a basic
rather than acidic pH mobile phase (23). The samples were ex-
tracted as above with the difference that the BondElut C18 car-
tridge was eluted with only 1.0 ml methanol/triethylamine (100:
0.1, vol/vol). The entire eluate was injected into the HPLC col-
umn (a Perkin-Elmer CR-C18 cartridge column, 3 
 
3
 
 0.46 cm, 3
 
m
 
m) using a Gilson ASPEC autosampler programmed to dilute
the eluate with 4.0 ml solvent A and inject the entire 5.0-ml di-
luted sample into the Rheodyne injector fitted with a 5.0 ml
stainless steel loop. The HPLC column was equilibrated for 10
min before sample injection of solvent A and after injection a lin-
ear gradient methanol/water/triethylamine (20:80:0.1 to 100:0:
0.1, vol/vol/vol, over 20 min) at a flow rate of 1.5 ml/min. The
UV absorbance of the column effluent was monitored for UV ab-
sorbance and quantitated as above. Fractions (0.2 min each) of the
column eluate were collected into polypropylene microtubes.
Fractions around the retention time of 12-HETE were dried in a
vacuum centrifuge and redissolved in 500 
 
m
 
l EIA buffer. The
fractions were assayed in duplicate using a 12(S)-HETE EIA (Per-
Septive Diagnostics, Cambridge, MA) according to kit instruc-
tions. The kit has a crossreactivity of less than 2% with 12-(R)-
HETE, 5-HETE, and 15-HETE. Immunoreactivity was found in
three consecutive fractions around the retention time of 12-
HETE and were summed to give the total concentration of 12-
(S)HETE in the samples.
 
Induction of Collagen-induced Arthritis.
 
Groups of age-matched
(10–20-wk-old) male DBA/1 mice of varying genotypes were
immunized at the base of the tail with 100 
 
m
 
g of chick type II col-
lagen in CFA on day 0 and 21. 1 
 
m
 
g of murine rIL-1
 
a
 
, diluted in
PBS containing 1 mg/ml BSA was administered subcutaneously
on days 45 and 46. This protocol causes all of the wild-type ani-
mals to exhibit a severe form of the disease (24, 25). Severity of
the symptoms of arthritis were assessed weekly, by an observer
unaware of the genotype of the animals, by inspection of the
paws (0 
 
5
 
 normal paw, 1 
 
5
 
 swelling and/or redness of one toe
or finger joint, 2 
 
5
 
 two or more joints involved, and 3 
 
5
 
 severe
arthritis in the entire paw; maximum score for each animal 
 
5
 
 12). 
1125
 
Griffiths et al.
On day 56, the mice were injected intraperitoneally with zymo-
san, and leukotriene production was measured as described above.
Blood was collected by cardiac puncture, and serum was prepared
and stored at 
 
2
 
20 C until assayed for anti-collagen antibody lev-
els. Knee joints were placed in formalin and processed as de-
scribed below.
 
Histopathology.
 
Knee joints were decalcified in Kristensen’s
solution, embedded in Paraplast plus, sectioned, stained, and ap-
proximately matched sections were examined by light micros-
copy on a Nikon FXA microscope.
 
Anti-collagen Antibody Levels.
 
IgG antibody levels against the
immunizing antigen were measured by standard ELISA method-
ology. Microtiter plates were coated with 0.5 
 
m
 
g/well chick col-
lagen, blocked with normal rabbit serum, and then incubated
with dilutions of the test sera. A standard curve was included on
each plate using known amounts (0.01–10 
 
m
 
g/ml) of a mono-
clonal anti-chick collagen antibody (A-2). A peroxidase-conju-
gated rabbit anti–mouse IgG was then added, followed by sub-
strate. The absorbance was measured at 450 nm and the amount
of antibody in each sample calculated by reference to the standard
curve.
 
Statistics.
 
The results are presented as the mean 
 
6
 
 SEM. Sta-
tistical analysis was done using Student’s 
 
t
 
 test with a Bonferroni
correction factor for multiple comparisons.
 
Results
 
The establishment of the DBA/1 ES cell line allowed the
investigation of induced FLAP mutant mice in the col-
lagen-induced arthritis model. Previously, we reported that
a targeting vector designed to inactivate FLAP in 129 ES
cells undergoes homologous recombination at a similar fre-
quency in nonisogenic DBA 252 ES cells (20). DBA/1 off-
spring of C57/DBA chimeric males demonstrated the mu-
tated FLAP allele at the expected 50% ratio. Normal 1:2:1
Mendelian segregation was observed in matings between
FLAP 
 
1
 
/
 
2
 
 males and females when identified by South-
ern blot analysis (Fig. 1). We observed no overt phenotypic
defects in the homozygous FLAP 
 
2
 
/
 
2
 
 DBA/1 mutants.
To verify that, similar to the situation seen in the 129/
FLAP-deficient mice, inactivation of the gene by homolo-
gous recombination leads to loss of leukotriene synthesis, zy-
mosan was injected intraperitoneally to trigger eicosanoid
synthesis associated with an increase in plasma protein ex-
travasation. The synthesis of LTE
 
4
 
 measured 30 min after
injection of zymosan was abolished in the FLAP-deficient
mice, whereas these mice made comparable levels of pros-
taglandins to wild type animals (Table 1). In addition, these
samples were analyzed by reverse phase HPLC with UV de-
tection. The major peptido-leukotriene product detected
in the wild-type mice was LTE
 
4
 
 with smaller amounts of
LTC
 
4
 
. However, no detectable peptido-leukotrienes were
present in the FLAP-deficient mice. The amount of HETEs
derived from the 5-, 12-, and 15-lipoxygenase pathway
were also measured. Pooled samples from mice of each
genotype were used. The only product detected was 12-
HETE in both the wild-type and the FLAP-deficient mice.
EIA of HPLC-purified fractions confirmed that this was
Figure 1. Southern blot analysis of DBA/1 offspring of FLAP 1/2
male and females. The offspring demonstrate normal Mendelian inheri-
tance of the wild type (16 kb) and the mutated (8 kb) alleles. The geno-
types are FLAP 1/1, lanes 7 and 9; FLAP 1/2, lanes 2, 3, 5, 6, and 8;
and FLAP 2/2, lanes 1 and 4.
 
Table 1.
 
Effect of FLAP Deficiency on Zymosan-stimulated Plasma Protein Extravasation and Eicosanoid Production
 
Genotype
of mice Experiment
Plasma protein
extravastion (OD 650) LTE
 
4 
 
(ng/ml)
6-keto-PGF1
 
a
 
(ng/ml)
12(S)-HETE
(ng/ml)
 
1/1
 
1 0.51 
 
6
 
 0.03 95 
 
6
 
 8 41 
 
6
 
 3 31.8
2 0.58 
 
6
 
 0.07 87 
 
6
 
 10 43 
 
6
 
 6 23.9
 
2/2
 
1 0.22 6 0.02* ,1* 40 6 4 19.5
2 0.31 6 0.05* ,1* 37 6 3 14.2
Groups of 6–9 male mice were injected intravenously with 0.2 ml of Evans blue dye to label plasma proteins. 1 mg of zymosan was then injected in-
traperitoneally. 30 min later the peritoneal cavity was lavaged and the amount of plasma protein quantified by measuring the absorbance of the cell-
free supernatant due to Evans blue–labeled proteins. Eicosanoid levels in the same supernatants were measured either by direct EIA on the fluids
(LTE4 and 6-keto-PGF1a) or EIA of HPLC-purified fractions from pooled samples (12(S)-HETE). Data are presented as mean 6 SEM. *P ,0.05.1126 Impaired Arthritis in 5-Lipoxygenase-activating Protein-deficient Mice
12(S)-HETE. The levels of 12(S)-HETE were slightly re-
duced in the FLAP-deficient mice (Table 1).
LTB4 levels reach a maximum between 2–3 h after injec-
tion of zymosan in this model. Therefore, separate groups of
mice were used to measure the levels of this eicosanoid.
LTB4 levels at 3 h after injection of zymosan were 1.52 6
0.23 ng/ml in wild-type animals but were below the limits
of detection of the assay (0.04 ng/ml) in the FLAP-defi-
cient mice. The increase in plasma protein extravastion as-
sociated with injection of zymosan was reduced by z50%
in the FLAP-deficient mice (Table 1).
The severity of collagen-induced arthritis in the FLAP-
deficient mice was reduced at all time points compared
with wild-type animals (Fig. 2). The total disease score
from days 21–56 (Fig. 2, area under the curve) was reduced
by a mean of 73%, P ,0.001 (Table 2). Heterozygous ani-
mals had a smaller, but significant decrease also, mean of
37%, P ,0.05. The reduced severity of arthritis was main-
tained even after injection of IL-1, which causes all of the
wild-type mice to exhibit a severe form of the disease (Fig.
2; Table 2). However, serum anti-collagen antibody levels
were similar in wild-type (1050 6 220 mg/ml) and FLAP
deficient mice (1200 6 23 mg/ml). Leukotriene levels in
zymosan-injected wild-type mice were similar to nonim-
munized animals (compare Table 1 with Table 2). Het-
erozygous animals had a slight reduction in LTE4 levels,
mean of 74% of control, and no detectable leukotriene was
produced in homozygous mice.
In the FLAP-deficient mice, there generally was an ab-
sence of inflammatory cells in the joint cavity or surround-
ing synovial tissue (Fig. 3 a). The articular cartilage was in-
tact, although there were regions of extensive depletion of
proteoglycans in the calcified and noncalcified cartilage.
Moreover, small pannus tongues coincided with the re-
gions of greatest proteoglycan loss in some animals. In both
the heterozygous and wild-type animals (Fig. 3, b and c),
the extent of disease was much more extensive. Generally,
these animals contained an extensive leukocyte infiltration
of the synovial connective tissue, plasma protein extravasa-
tion into the synovial cavity, and variable amounts of artic-
ular cartilage destruction.
Figure 2. Collagen-induced arthritis in FLAP deficient mice. DBA/1
mice were immunized with chick type II collagen on day 0 and 21. IL-1
was administered subcutaneously on days 45 and 46 to trigger an arthritic
flare. Disease severity was scored by observation of the paws for redness
and swelling. Open circles, 1/1 mice; closed triangles, 1/2 mice; open
squares, 2/2 mice. Results are mean 6 SEM, n 5 3 experiments.
Table 2. Effect of FLAP Deficiency on Collagen-induced Arthritis
Genotype of mice Experiment
Severity score
day 56 AUC
Percentage of mice
with arthritis
LTE4
(ng/ml)
1/1 1 10.2 6 1.6 144.9 100 84 6 15
2 8.8 6 2.1 158.2 100 145 6 19
3 11.0 6 0.8 163.1 100 104 6 15
1/2 1 8.1 6 1.6 123.6 86 71 6 7
2 6.4 6 2.1 93.8 71 100 6 23
3 6.8 6 1.8 79.1 74 74 6 11
2/2 1 3.3 6 1.4 55.7 75 ,1
2 4.8 6 1.9 52.5 71 ,1
3 1.7 6 0.7 18.6 75 ,1
Groups of 4–9 male mice were immunized with 100 mg chick type II collagen on days 0 and 21. 1 mg of rIL-1a was injected subcutaneously on days
45 and 46. The severity of arthritis was assessed by scoring the degree of inflammation in each paw weekly. The average total severity for each group
of mice was calculated as area under the curve (AUC) for days 21–56. On day 56, 1 mg zymosan was injected intraperitoneally. LTE4 levels in peri-
toneal lavage were measured by EIA.1127 Griffiths et al.
Discussion
The ability to modulate the genetic composition of mice
selectively is a powerful tool to study the role of a gene
product in both physiological and pathophysiological pro-
cesses. Mice with a deficiency in the FLAP gene are phe-
notypically normal and reproduce with the expected Men-
delian ratio of homozygotes to heterozygotes. Leukotriene
production in vivo is absent in these mice, confirming the
substantial body of in vitro evidence indicating that FLAP
is a necessary component of the 5-LO pathway (8, 10).
The slight reduction in 12(S)-HETE production was unan-
ticipated and may suggest a role for FLAP in this pathway.
This is a subject that requires further investigation. The
Figure 3. Light microscopy of
the knee joint from FLAP 2/2,
1/2, and 1/1 mice. In the
FLAP knockout mice (a) there is
an absence of inflammatory cells in
the synovial tissue surrounding
the joint cavity. An occasional
pannus tongue (arrow) was ob-
served and tongues generally
lacked a large cellular component.
The femoral condyle (f) articular
cartilage was intact, although re-
gions of proteoglycan depletion
(arrowhead) were observed and
these typically coincided with the
pannus extensions. In the het-
erozygous mice (b), the articular
cartilage was removed down to the
tidemark (arrowheads) over large re-
gions of the femoral condyle (f).
Several pannus tongues (arrow)
and an increased inflammatory cell
influx into the surrounding syn-
ovial tissue were observed. In the
wild-type mice (c), the destruction
of the femoral condyle (f) articular
cartilage (arrowheads) was much
more extensive. In addition, some
plasma proteins and cells (*) were
observed within the joint cavity.
The pannus tongues (arrow) and in-
creased cellularity of the synovial
tissue were similar to that observed
in the heterozygous mice. Original
magnification, 360.1128 Impaired Arthritis in 5-Lipoxygenase-activating Protein-deficient Mice
presence of high levels of prostaglandins in the FLAP-defi-
cient mice confirms that the interaction of FLAP with the
5-LO pathway is selective.
This defect in leukotriene production results in de-
creased plasma protein extravasation in the peritoneal cav-
ity in response to an injection of zymosan. This agrees with
pharmacological studies with 5-LO inhibitors, which also
reduce this response (26). The magnitude of the inhibiton
in the DBA/1 mice is less than that observed in the 129
strain. This may be due to the contribution of mast cell
amines to the response, which may vary in different strains.
Collagen-induced arthritis in the mouse is an autoim-
mune disease produced by immunizing mice with heterol-
ogous type II collagen. This form of collagen is found in
articular cartilage and the immune response against the im-
munizing antigen leads to a chronic, destructive polyarthri-
tis that has certain features in common with human rheu-
matoid arthritis. The disease is only produced in certain
susceptible strains of mice, mainly those of the H-2q haplo-
type, but multiple genes contribute to this susceptibility
(15). The DBA/1 mouse has been the strain most com-
monly used to study this disease. The 129 ES cell lines,
normally used for gene targeting, generate mice that are not
susceptible to collagen-induced arthritis. Therefore, to study
this model it is necessary to breed the gene-deficient mouse
to the DBA/1 background. Because the disease is poly-
genic, it is not clear how many generations of breeding are
required to ensure that any diminution in severity of dis-
ease observed is due to the lack of the targeted gene, rather
than to the fact that the mice may not be congenic. There-
fore, we have recently developed a ES cell line from DBA/1
mice, that has allowed us to circumvent this problem by gene
targeting directly on the arthritis-susceptible background.
We have previously reported that collagen-induced ar-
thritis can be prevented by the administration of a potent
and selective LTB4 receptor antagonist, implicating prod-
ucts of the 5-LO pathway as mediators of this disease (16).
However, arachidonic acid metabolites derived from the
monooxygenase pathway can also act through this receptor,
e.g, 12(R)-HETE (27), and it has recently been reported that
a FLAP inhibitor does not prevent collagen-induced arthri-
tis alone, but only when coadministered with an inhibitor
of prostaglandin synthesis (17). This latter study suggests that
inhibition of the 5-LO pathway alone is not sufficient to in-
hibit disease. However, our experiments with FLAP-defi-
cient mice provide very strong evidence that products of
the 5-LO pathway are essential for the development of this
disease. We do not believe that the reduction in 12(S)-
HETE production contributes to the reduced inflamma-
tory responses in these mice because, unlike 12(R)-HETE,
this product does not bind to the LTB4 receptor and is not
chemotactic for leukocytes (25).
The animals were successfully immunized against col-
lagen, as judged by the fact that they make normal levels of
antibody, but exhibit a profound reduction in the signs of
arthritis. This result is in agreement with our previous stud-
ies with an LTB4 receptor antagonist. The observed effects
are particularly impressive given the fact that we challenged
the mice with IL-1, which causes control mice to develop
a very severe form of the disease.
In summary, FLAP-deficient mice are phenotypically
normal but exhibit a complete defect in leukotriene pro-
duction. They also show reduced acute and chronic in-
flammatory responses, confirming the important role of
leukotrienes as mediators of the inflammatory response in
mice.
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